CN116327758A - 用阿曲生坦治疗IgA肾病的方法 - Google Patents

用阿曲生坦治疗IgA肾病的方法 Download PDF

Info

Publication number
CN116327758A
CN116327758A CN202310043260.6A CN202310043260A CN116327758A CN 116327758 A CN116327758 A CN 116327758A CN 202310043260 A CN202310043260 A CN 202310043260A CN 116327758 A CN116327758 A CN 116327758A
Authority
CN
China
Prior art keywords
weeks
subject
atrasentan
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202310043260.6A
Other languages
English (en)
Chinese (zh)
Inventor
P·T·弗罗里希
A·J·金
C·拉马钱德拉
S·B·诺恩伯格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chinook Medical
Original Assignee
Chinook Medical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chinook Medical filed Critical Chinook Medical
Publication of CN116327758A publication Critical patent/CN116327758A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
CN202310043260.6A 2019-12-17 2020-12-16 用阿曲生坦治疗IgA肾病的方法 Pending CN116327758A (zh)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US201962949115P 2019-12-17 2019-12-17
US62/949,115 2019-12-17
US202063005003P 2020-04-03 2020-04-03
US63/005,003 2020-04-03
US202063072699P 2020-08-31 2020-08-31
US63/072,699 2020-08-31
US202063084739P 2020-09-29 2020-09-29
US63/084,739 2020-09-29
US202063125205P 2020-12-14 2020-12-14
US63/125,205 2020-12-14
PCT/US2020/065311 WO2021126977A1 (en) 2019-12-17 2020-12-16 Methods of treating iga nephropathy with atrasentan
CN202080007568.XA CN113272013A (zh) 2019-12-17 2020-12-16 用阿曲生坦治疗IgA肾病的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202080007568.XA Division CN113272013A (zh) 2019-12-17 2020-12-16 用阿曲生坦治疗IgA肾病的方法

Publications (1)

Publication Number Publication Date
CN116327758A true CN116327758A (zh) 2023-06-27

Family

ID=76478538

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202310043260.6A Pending CN116327758A (zh) 2019-12-17 2020-12-16 用阿曲生坦治疗IgA肾病的方法
CN202080007568.XA Pending CN113272013A (zh) 2019-12-17 2020-12-16 用阿曲生坦治疗IgA肾病的方法
CN202310043259.3A Pending CN116173014A (zh) 2019-12-17 2020-12-16 用阿曲生坦治疗IgA肾病的方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202080007568.XA Pending CN113272013A (zh) 2019-12-17 2020-12-16 用阿曲生坦治疗IgA肾病的方法
CN202310043259.3A Pending CN116173014A (zh) 2019-12-17 2020-12-16 用阿曲生坦治疗IgA肾病的方法

Country Status (21)

Country Link
US (11) US20210353593A1 (cg-RX-API-DMAC7.html)
EP (2) EP4076652B1 (cg-RX-API-DMAC7.html)
JP (3) JP7624995B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230015874A (cg-RX-API-DMAC7.html)
CN (3) CN116327758A (cg-RX-API-DMAC7.html)
AU (1) AU2020404984A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022012075A2 (cg-RX-API-DMAC7.html)
CA (1) CA3161516A1 (cg-RX-API-DMAC7.html)
DK (1) DK4076652T3 (cg-RX-API-DMAC7.html)
FI (1) FI4076652T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20260121T1 (cg-RX-API-DMAC7.html)
IL (1) IL293921A (cg-RX-API-DMAC7.html)
LT (1) LT4076652T (cg-RX-API-DMAC7.html)
MX (1) MX2022007471A (cg-RX-API-DMAC7.html)
PH (1) PH12022551456A1 (cg-RX-API-DMAC7.html)
PL (1) PL4076652T3 (cg-RX-API-DMAC7.html)
PT (1) PT4076652T (cg-RX-API-DMAC7.html)
RS (1) RS67746B1 (cg-RX-API-DMAC7.html)
SI (1) SI4076652T1 (cg-RX-API-DMAC7.html)
TW (3) TW202615002A (cg-RX-API-DMAC7.html)
WO (1) WO2021126977A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20260121T1 (hr) 2019-12-17 2026-03-13 Chinook Therapeutics, Inc. Farmaceutski prihvatljiva sol atrasentana za uporabu u postupku za liječenje iga nefropatije
CN114910647A (zh) * 2022-05-07 2022-08-16 浙江大学 细丝蛋白-A-IgG抗体在制备检测血管内皮损伤试剂盒中的应用
WO2023220930A1 (en) * 2022-05-17 2023-11-23 Increvet, Inc. Veterinary pharmaceutical formulations cross-references to related applications
JP2025517355A (ja) * 2022-05-19 2025-06-05 チヌーク セラピューティクス,インコーポレイテッド アトラセンタンを用いた巣状分節性糸球体硬化症の治療方法
WO2024073672A1 (en) 2022-09-30 2024-04-04 Travere Therapeutics, Inc. Combination therapy with sparsentan and a sglt2 inhibitor for treating kidney diseases or disorders
US20260130933A1 (en) * 2022-10-05 2026-05-14 Daewoong Pharmaceutical Co., Ltd. Pharmaceutical composition for prevention or treatment of nephropathy and/or diabetes mellitus, comprising enavogliflozin
AU2023366516A1 (en) * 2022-10-28 2025-05-15 Aduro Biotech Holdings, Europe B.V. Treatment of iga nephropathy using an endothelin receptor antagonist and an april binding antibody
WO2024099272A1 (zh) * 2022-11-07 2024-05-16 信瑞诺医药(上海)有限公司 用于治疗IgA肾病的内皮素受体拮抗剂和糖皮质激素的组合
TW202604476A (zh) * 2024-06-21 2026-02-01 大陸商深圳信立泰藥業股份有限公司 內皮素a(eta)受體拮抗劑聯用sglt-2抑制劑的醫藥用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011163085A2 (en) * 2010-06-24 2011-12-29 Morehouse School Of Medicine Method and compositions use for endothelin-1 related kidney diseases
CN105246512A (zh) * 2013-04-30 2016-01-13 艾伯维公司 使用阿曲生坦用于改善脂质概况的方法
CN105324395A (zh) * 2013-03-08 2016-02-10 艾伯维公司 治疗急性肾损伤的方法
CN110049764A (zh) * 2016-10-13 2019-07-23 雷特罗芬公司 用于治疗肾脏疾病或病症的联苯磺酰胺化合物

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5236940A (en) 1988-12-15 1993-08-17 Rhone-Poulenc Sante Pharmaceutical compositions, 2-benzothiazolamine derivatives, and their preparation
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US7208517B1 (en) 1994-08-19 2007-04-24 Abbott Labortories Endothelin antagonists
US6946481B1 (en) 1994-08-19 2005-09-20 Abbott Laboratories Endothelin antagonists
US7365093B2 (en) 1994-08-19 2008-04-29 Abbott Laboratories Endothelin antagonists
US20020062121A1 (en) 1995-05-16 2002-05-23 Karl Tryggvason Perfusion apparatus and methods for pharmaceutical delivery
ES2259803T3 (es) 1996-02-13 2006-10-16 Abbott Laboratories Nuevos derivados de pirrolidina sustituidos con benzo-1,3-dioxolilo y benzofuranilo como antagonistas de endostelina.
US20040191774A1 (en) 2001-09-11 2004-09-30 Moskowitz David W Endothelin-1 promoter polymorphism
AU2003221042A1 (en) 2002-03-22 2003-10-08 Kissei Pharmaceutical Co., Ltd. Preventive or therapeutic agent for kidney disease
US20070134247A9 (en) 2002-04-12 2007-06-14 Ramot At Tel Aviv University Ltd. Prevention of brain inflammation as a result of induced autoimmune response
US20030229906A1 (en) 2002-04-15 2003-12-11 Gelman Irwin H. Methods and compositions for the treatment of disorders of HIV infection
US9388427B2 (en) 2002-12-02 2016-07-12 Biovec, Llc In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors
US7410483B2 (en) 2003-05-23 2008-08-12 Novare Surgical Systems, Inc. Hand-actuated device for remote manipulation of a grasping tool
WO2005120571A2 (en) 2004-06-07 2005-12-22 Ramot At Tel Aviv University Ltd. Method of passive immunization against disease or disorder characterized by amyloid aggregation with diminished risk of neuroinflammation
WO2006034234A1 (en) 2004-09-17 2006-03-30 Abbott Laboratories Crystalline form 3 of atrasentan hydrochloride
WO2006034084A1 (en) 2004-09-17 2006-03-30 Abbott Laboratories Crystalline form 2 of atrasentan hydrochloride
WO2006034085A1 (en) 2004-09-17 2006-03-30 Abbott Laboratories Crystalline form of atrasentan hydrochloride
US20060189675A1 (en) 2004-09-17 2006-08-24 Steve King Crystalline form of a drug
WO2007109244A2 (en) 2006-03-21 2007-09-27 Morehouse School Of Medicine Novel nanoparticles for delivery of active agents
KR20080108570A (ko) * 2006-03-27 2008-12-15 제넨테크, 인크. 신장 질환을 치료하는 방법
WO2007119214A2 (en) 2006-04-13 2007-10-25 Actelion Pharmaceuticals Ltd Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis
ZA200902814B (en) 2007-01-16 2010-08-25 Musc Found For Res Dev Compositions and methods for diagnosing, treating, and preventing prostate conditions
CN101801936B (zh) 2007-07-31 2012-10-03 吉利德科罗拉多公司 安立生坦的代谢物和衍生物
CA2697057A1 (en) 2007-08-22 2009-02-26 Gilead Colorado, Inc. Therapy for complications of diabetes
US20120083421A1 (en) 2008-10-16 2012-04-05 The Trustees Of Columbia University In The City Of New York Use of urinary ngal to diagnose and monitor hiv-associated nephropathy (hivan)
WO2010114801A1 (en) 2009-03-31 2010-10-07 Ligand Pharmaceuticals Inc. Oral formulations of diphenylsulfonamide endothelin and angiotensin ii receptor agonists to treat elevated blood pressure and diabetic nephropathy
WO2011070049A1 (en) 2009-12-09 2011-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Endothelin inhibitors for the treatment of rapidly progressive glomerulonephritis
CN103025670B (zh) 2010-07-28 2016-08-10 日本电气硝子株式会社 荧光体封入用毛细管的制造方法、荧光体封入用毛细管、波长变换部件和波长变换部件的制造方法
PE20160221A1 (es) 2013-07-08 2016-05-22 Abbvie Inc Formas de dosificacion farmaceuticas estabilizadas que comprenden atrasentan
NL2011406C2 (en) 2013-09-06 2015-03-10 Bionovion Holding B V Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
US8962675B1 (en) 2013-09-12 2015-02-24 Abbvie Inc. Atrasentan mandelate salts
WO2016073846A1 (en) * 2014-11-07 2016-05-12 Abbvie Inc. Methods of treating ckd using predictors of fluid retention
NL2014108B1 (en) 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
US20170014386A1 (en) 2015-07-16 2017-01-19 Abbvie, Inc. Treatment of Multidrug-Resistant Nephrotic Syndrome (MDR-NS) in Children
IL300122A (en) * 2015-11-18 2023-03-01 Merck Sharp ַ& Dohme Llc Substances that bind to PD1 and/or LAG3
CA3010593C (en) 2016-01-05 2024-02-13 University Of Leicester Methods for inhibiting fibrosis in a subject in need thereof
IL294410B2 (en) 2016-11-23 2024-02-01 Chemocentryx Inc A method for the treatment of focal segmental tuberous sclerosis
MX386699B (es) 2017-10-11 2025-03-19 Chemocentryx Inc Tratamiento de glomerulosclerosis segmentaria focal con antagonistas ccr2
LT3716979T (lt) 2017-11-30 2025-07-10 Idorsia Pharmaceuticals Ltd 4-pirimidinsulfamido darinio derinys su sglt-2 inhibitoriumi, skirtas su endotelinu susijusių ligų gydymui
US20220304979A1 (en) 2019-12-17 2022-09-29 Chinook Therapeutics, Inc. Methods of reducing disease flares
HRP20260121T1 (hr) 2019-12-17 2026-03-13 Chinook Therapeutics, Inc. Farmaceutski prihvatljiva sol atrasentana za uporabu u postupku za liječenje iga nefropatije
US20230270718A1 (en) 2020-04-10 2023-08-31 Chinook Therapeutics, Inc. Methods of treating diabetic kidney disease
US20220243994A1 (en) 2021-02-04 2022-08-04 Northrop Grumman Systems Corporation Metal woodpile capillary wick

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011163085A2 (en) * 2010-06-24 2011-12-29 Morehouse School Of Medicine Method and compositions use for endothelin-1 related kidney diseases
CN105324395A (zh) * 2013-03-08 2016-02-10 艾伯维公司 治疗急性肾损伤的方法
CN105246512A (zh) * 2013-04-30 2016-01-13 艾伯维公司 使用阿曲生坦用于改善脂质概况的方法
CN110049764A (zh) * 2016-10-13 2019-07-23 雷特罗芬公司 用于治疗肾脏疾病或病症的联苯磺酰胺化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
王琦等: "局部进展性肾癌综合治疗的研究进展", 临床泌尿外科杂志, vol. 27, no. 12, 31 December 2012 (2012-12-31), pages 952 - 955 *

Also Published As

Publication number Publication date
CA3161516A1 (en) 2021-06-24
US20220288027A1 (en) 2022-09-15
JP2026090302A (ja) 2026-06-02
LT4076652T (lt) 2026-02-25
DK4076652T3 (da) 2026-03-02
JP2023507739A (ja) 2023-02-27
KR20230015874A (ko) 2023-01-31
US20230355580A1 (en) 2023-11-09
PH12022551456A1 (en) 2023-10-23
EP4710928A2 (en) 2026-03-18
IL293921A (en) 2022-08-01
US12582631B2 (en) 2026-03-24
EP4076652B1 (en) 2025-12-03
BR112022012075A2 (pt) 2022-08-30
CN113272013A (zh) 2021-08-17
MX2022007471A (es) 2022-08-17
US11491137B2 (en) 2022-11-08
PL4076652T3 (pl) 2026-03-23
US20210353593A1 (en) 2021-11-18
US20240108599A1 (en) 2024-04-04
US20230364055A1 (en) 2023-11-16
US12121509B2 (en) 2024-10-22
EP4710928A3 (en) 2026-04-15
EP4076652A1 (en) 2022-10-26
JP2025060686A (ja) 2025-04-10
SI4076652T1 (sl) 2026-03-31
JP7821870B2 (ja) 2026-02-27
TW202545517A (zh) 2025-12-01
US20230129646A1 (en) 2023-04-27
US20230355579A1 (en) 2023-11-09
JP7624995B2 (ja) 2025-01-31
US20220304978A1 (en) 2022-09-29
TW202130350A (zh) 2021-08-16
US12521369B2 (en) 2026-01-13
FI4076652T3 (fi) 2026-02-10
CN116173014A (zh) 2023-05-30
TW202615002A (zh) 2026-04-16
RS67746B1 (sr) 2026-03-31
US12370174B2 (en) 2025-07-29
TWI914232B (zh) 2026-02-01
AU2020404984A1 (en) 2022-07-14
US20220288026A1 (en) 2022-09-15
HRP20260121T1 (hr) 2026-03-13
TWI875895B (zh) 2025-03-11
US20250281454A1 (en) 2025-09-11
PT4076652T (pt) 2026-02-12
WO2021126977A1 (en) 2021-06-24
WO2021126977A9 (en) 2021-07-22
US20250120945A1 (en) 2025-04-17
EP4076652A4 (en) 2024-01-03
US11998526B2 (en) 2024-06-04

Similar Documents

Publication Publication Date Title
US11491137B2 (en) Methods of improving renal function
US20220304979A1 (en) Methods of reducing disease flares
ES3062063T3 (en) A pharmaceutically acceptable salt of atrasentan for use in a method of treating iga nephropathy
HK40094573A (en) Methods of treating iga nephropathy with atrasentan
HK40059453A (en) Methods of treating iga nephropathy with atrasentan
BR122023026537A2 (pt) Uso de atrasentan para tratar nefropatia por iga
US20250352511A1 (en) Methods of treating focal segmental glomerulosclerosis with atrasentan

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination